# Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

> **NCT01465347** · PHASE1,PHASE2 · COMPLETED · sponsor: **Diffusion Pharmaceuticals Inc** · enrollment: 59 (actual)

## Conditions studied

- Glioblastoma
- GBM
- Glioma

## Interventions

- **DRUG:** Trans Sodium Crocetinate (TSC)

## Key facts

- **NCT ID:** NCT01465347
- **Lead sponsor:** Diffusion Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-11
- **Final completion:** 2016-02
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2017-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465347, "Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01465347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*